EXT 608
Alternative Names: EXT-608Latest Information Update: 18 Sep 2023
At a glance
- Originator Extend Biosciences
- Class Calcium regulators; Drug conjugates; Peptide hormones; Vitamins
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Hypoparathyroidism
Most Recent Events
- 13 Jun 2023 Extend Biosciences completes a phase I trial in Hyporparathyroidism (In volunteers) in USA (SC) (NCT05408663)
- 11 May 2023 Interim adverse event, pharmacokinetics and pharmacodynamics data from phase I trial in Hypoparathyroidism released by Extend Biosciences
- 11 May 2023 Extend Biosciences plans a phase II trial for Hypoparathyroidism